What it's for (Indications)
- Bevacizumab, a recombinant humanized monoclonal antibody, is indicated for the treatment of various types of cancer.
- Its approved uses include, but are not limited to, metastatic colorectal cancer (mCRC) in combination with fluorouracil-based chemotherapy for first- or second-line treatment; non-squamous non-small cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel for first-line treatment in patients with unresectable, locally advanced, recurrent or metastatic disease; glioblastoma in adult patients with progressive disease following prior therapy; metastatic renal cell carcinoma (mRCC) in combination with interferon alfa; persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan; epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel for platinum-sensitive disease, or in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin for platinum-resistant disease; and hepatocellular carcinoma in combination with atezolizumab for patients who have not received prior systemic therapy.
- These indications underscore its broad utility as an anti-angiogenic agent in oncology, targeting the vascular supply essential for tumor growth and metastasis across these diverse cancer types.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Bevacizumab is administered intravenously, and its precise dosage is meticulously calculated based on the patient's body weight and the specific cancer indication being treated. Typical dosing regimens range from 5 mg/kg to 15 mg/kg, generally administered every 2 or 3 weeks. For instance, in metastatic colorectal cancer, common doses are 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks. For non-squamous non-small cell lung cancer, it is typically 15 mg/kg every 3 weeks in combination with platinum-based chemotherapy. Patients with glioblastoma generally receive 10 mg/kg every 2 weeks. The initial dose should be infused slowly over 90 minutes to monitor for infusion reactions. If the first infusion is well tolerated, subsequent doses may be administered over 60 or 30 minutes, at the discretion of the treating physician. It is paramount that administration occurs under the direct supervision of a healthcare professional experienced in oncology, within an appropriate clinical setting. The exact dose, frequency, and duration of treatment are determined by the treating oncologist, considering the patient's specific cancer type, stage, prior treatments, clinical response, and management of any potential adverse events. |
Safety & Warnings
Common Side Effects
- Bevacizumab is associated with a wide spectrum of side effects, which can vary significantly in severity and incidence depending on the individual patient and the specific indication.
- Common adverse reactions observed across various clinical trials include hypertension, proteinuria, fatigue, asthenia, headache, diarrhea, abdominal pain, constipation, nausea, vomiting, stomatitis, epistaxis (nosebleeds), rhinorrhea, dry skin, and alopecia.
- More serious, albeit less frequent, adverse events include arterial thromboembolic events (e.
- g.
- , myocardial infarction, stroke, transient ischemic attack), venous thromboembolic events (e.
- g.
- , deep vein thrombosis, pulmonary embolism), congestive heart failure, severe proteinuria potentially leading to nephrotic syndrome, posterior reversible encephalopathy syndrome (PRES), hypersensitivity reactions including anaphylaxis, severe dermatologic reactions, and ovarian failure.
- Due to its anti-angiogenic mechanism, there is also a significant risk of impaired wound healing, various types of hemorrhage, and gastrointestinal perforation or fistula formation.
- Patients must be diligently monitored for these potential complications throughout the entire course of treatment with bevacizumab, and prompt intervention is crucial.
Serious Warnings
- Black Box Warning: Bevacizumab carries several prominent Black Box Warnings, which highlight severe and potentially fatal adverse effects that necessitate careful patient selection, vigilant monitoring, and prompt management. These include: 1. **Gastrointestinal Perforation:** Bevacizumab treatment significantly increases the risk of gastrointestinal perforation and fistula formation, including tracheoesophageal fistulas. These events can be life-threatening and may manifest with symptoms such as severe abdominal pain, nausea, vomiting, constipation, and fever. The incidence of gastrointestinal perforation can vary, ranging from less than 1% to up to 2% depending on the specific cancer type and concomitant therapies. Patients presenting with symptoms suggestive of gastrointestinal perforation must have bevacizumab permanently discontinued. 2. **Surgery and Wound Healing Complications:** The use of bevacizumab is associated with an increased risk of impaired wound healing and serious, sometimes fatal, wound dehiscence and fistula formation. This risk is particularly elevated in the perioperative period. Treatment with bevacizumab should be withheld for at least 28 days prior to any elective surgery. Furthermore, it should not be initiated for at least 28 days following major surgery and until the surgical wound is fully healed. Complications arising from impaired wound healing may necessitate surgical intervention and can be life-threatening. 3. **Hemorrhage:** Severe and sometimes fatal hemorrhage, including hemoptysis, gastrointestinal hemorrhage, central nervous system (CNS) hemorrhage, and vaginal bleeding, has been observed in patients treated with bevacizumab. The risk of CNS hemorrhage is particularly elevated in patients with glioblastoma. Bevacizumab should be permanently discontinued in patients who experience a severe hemorrhage (defined as Grade 3 or 4 bleeding). Patients with recent significant hemorrhage or a predisposition to bleeding should be carefully evaluated and the risks thoroughly weighed before initiating therapy. 4. **Arterial Thromboembolic Events (ATEs):** Bevacizumab increases the risk of serious, sometimes fatal, arterial thromboembolic events, such as myocardial infarction, stroke, transient ischemic attack (TIA), and other thrombotic events. This risk is notably higher in patients with a history of arterial thromboembolism. Bevacizumab should be permanently discontinued in patients who experience a severe ATE. These warnings underscore the critical importance of comprehensive risk assessment, close clinical observation, and immediate management of adverse events during bevacizumab administration.
- Beyond the critical black box warnings, several other significant warnings are imperative for healthcare professionals and patients to be aware of during bevacizumab therapy.
- Patients should be closely monitored for the development or worsening of hypertension, which frequently requires medical management with antihypertensive medications and, in severe cases, may necessitate temporary interruption or permanent discontinuation of bevacizumab.
- Proteinuria is a common occurrence and should be regularly assessed via urine dipstick; severe proteinuria (Grade 4) leading to nephrotic syndrome mandates permanent discontinuation.
- The risk of hemorrhage, while critically detailed in the black box, also extends to less severe bleeding events such as epistaxis and gingival bleeding.
- Fistula formation, including tracheoesophageal, enterovaginal, and other types of fistulas, can occur at various sites.
- There is an increased risk of arterial thromboembolic events, such as myocardial infarction, stroke, or transient ischemic attack, particularly in patients with a history of arterial disease.
- Venous thromboembolic events, including deep vein thrombosis and pulmonary embolism, also carry an elevated risk.
- Other concerns include congestive heart failure, potentially fatal hypersensitivity reactions including anaphylaxis, and the risk of ovarian failure which may lead to infertility.
- Regular monitoring, proactive management of these potential complications, and patient education are essential components of safe bevacizumab administration.
How it Works (Mechanism of Action)
Bevacizumab exerts its therapeutic effect by precisely binding to and neutralizing vascular endothelial growth factor A (VEGF-A), a pivotal signaling protein that plays a central role in pathological angiogenesis. VEGF-A is a potent inducer of endothelial cell proliferation, migration, and survival, driving the formation of new blood vessels (neovascularization) that are essential for tumor growth, invasion, and metastasis. By specifically targeting VEGF-A, bevacizumab prevents its interaction with its receptors, primarily VEGFR-1 and VEGFR-2, which are located on the surface of endothelial cells within the tumor microenvironment. This inhibition effectively suppresses tumor angiogenesis, thereby limiting the blood supply to the tumor, hindering its growth, and potentially reducing its metastatic potential. The disruption of tumor vasculature can also lead to a normalization of existing, often aberrant, tumor blood vessels, which may transiently improve the delivery and efficacy of co-administered chemotherapeutic agents. This targeted anti-angiogenic approach is foundational to bevacizumab's role in multimodal cancer therapy, aiming to starve the tumor of necessary resources for survival and proliferation.
Commercial Brands (Alternatives)
No other brands found for this formula.